Bentley Pharmaceuticals (BNT) Receives Broad U.S. Patent Protection for Its Intranasal Drug Delivery Technology
7/19/2007 10:54:22 AM
EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office has issued patent number 7,244,703 entitled “Pharmaceutical Compositions and Methods for Peptide Treatment.” This patent extends coverage for Bentley’s current intranasal drug delivery technology utilizing CPE-215® beyond insulin to include delivery of other therapeutically effective, pharmaceutically active peptides, peptidomimetics and proteins. Many such molecules are already in commercial use in chronic clinical indications employing injections that could benefit patients through enabling of nasal administration formats. In September 2006, Bentley received a U.S. patent covering Bentley’s intranasal delivery spray for insulin.
comments powered by